Company intelligence / Profile preview

SATT Conectus

Strasbourg, Grand Est, Franceconectus.fr ↗

Ownership: Private
Development stage: Other

Overview

SATT Conectus does not develop drugs directly but invests in and transfers early-stage academic innovations with established proof of concept. Recent collaborations have led to clinical development of monoclonal antibodies against BK virus and novel therapies for multiple sclerosis through licensing agreements with biotech companies such as SpikImm and Find Therapeutics.

Therapeutic areas: OncologyNeurologyInfectious Diseases
Modalities: Monoclonal antibodySmall molecule
Industry: Investors

Partnerships

SpikImm – exclusive license/collaboration on anti-BK virus mAbsFind Therapeutics – exclusive license/collaboration on remyelination therapy for MS/demyelinating diseasesNumerous public research institutions including University of Strasbourg, INSERM, CNRS laboratories, engineering schools in Alsace region

Beyond the preview

Go deeper on SATT Conectus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SATT Conectus.

Explore the full profile